Commentary: real-world triple therapy experience treating hepatitis C virus.
Department of Gastroenterology, Ninewells Hospital & Medical School, Dundee, UK. theron@nhs.net.
T
T
Heron
M H
MH
Miller
J F
JF
Dillon
D000998:Antiviral Agents / Q000009:adverse effects*; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D008103:Liver Cirrhosis / Q000188:drug therapy*; D008297:Male; D009842:Oligopeptides / Q000009:adverse effects*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D012254:Ribavirin / Q000009:adverse effects*
D000998:Antiviral Agents; D016898:Interferon-alpha; D009842:Oligopeptides; D011092:Polyethylene Glycols; D012254:Ribavirin